pharma · Advanced Malignant Tumors · Metastatic Pancreatic Ductal Adenocarcinoma
Akeso
Akeso is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Malignant Tumors, Metastatic Pancreatic Ductal Adenocarcinoma, Atopic Dermatitis. NovaPharmaNews links 3 clinical progr
CN HQ
2012 Founded
112 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2012
- Employees
- 112
- Programs
- 3
- Drugs
- 8
- Patents
- 0
AK112-210
Phase 2 · small molecule · Metastatic Pancreatic Ductal Adenocarcinoma
AK112-210 for Metastatic Pancreatic Ductal Adenocarcinoma is a Phase 2 program (small_molecule) at Akeso with 1 ClinicalTrials.gov record(s).
Internal code AK112-210
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Akeso
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- active
- Trials
- 1